“First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026066. doi:10.4084/MJHID.2026.066.